atenolol has been researched along with Death, Sudden, Cardiac in 17 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the actions of beta-blocker (atenolol) and ACE inhibitor (enalapril) for the secondary prevention of the main cardiac complications after acute myocardial infarction (AMI)." | 9.08 | Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group. ( Fan, Z; Wu, N, 1997) |
| "The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
| "To investigate the actions of beta-blocker (atenolol) and ACE inhibitor (enalapril) for the secondary prevention of the main cardiac complications after acute myocardial infarction (AMI)." | 5.08 | Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group. ( Fan, Z; Wu, N, 1997) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "The patient had no further arrhythmias on quinidine for 6 years until he inexplicably discontinued his medication and died suddenly shortly thereafter." | 1.30 | Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. ( Feld, GK; Finneran, W; Garg, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reno, CM | 1 |
| Skinner, A | 1 |
| Bayles, J | 1 |
| Chen, YS | 1 |
| Daphna-Iken, D | 1 |
| Fisher, SJ | 1 |
| Abu-Zeitone, A | 1 |
| Peterson, DR | 1 |
| Polonsky, B | 1 |
| McNitt, S | 1 |
| Moss, AJ | 1 |
| Morin, DP | 1 |
| Oikarinen, L | 1 |
| Viitasalo, M | 1 |
| Toivonen, L | 1 |
| Nieminen, MS | 2 |
| Kjeldsen, SE | 2 |
| Dahlöf, B | 3 |
| John, M | 1 |
| Devereux, RB | 2 |
| Okin, PM | 2 |
| Aronow, WS | 1 |
| Lindholm, LH | 2 |
| Edelman, JM | 1 |
| Ibsen, H | 2 |
| Borch-Johnsen, K | 1 |
| Olsen, MH | 2 |
| Snapinn, S | 1 |
| Wachtell, K | 2 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Lip, GY | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Thygesen, K | 1 |
| Adamson, PB | 1 |
| Huang, MH | 1 |
| Vanoli, E | 1 |
| Foreman, RD | 1 |
| Schwartz, PJ | 1 |
| Hull, SS | 1 |
| Raza, A | 1 |
| Killip, T | 1 |
| Goodman, S | 1 |
| Hill, C | 1 |
| Bata, I | 1 |
| Fung, A | 1 |
| Higginson, L | 1 |
| Lam, J | 1 |
| Massel, D | 1 |
| McCans, J | 1 |
| Nasmith, J | 1 |
| Stanton, E | 1 |
| Thompson, C | 1 |
| Warnica, W | 1 |
| Langer, A | 1 |
| Lurje, L | 1 |
| Wennerblom, B | 1 |
| Tygesen, H | 1 |
| Karlsson, T | 1 |
| Hjalmarson, A | 1 |
| Wu, N | 1 |
| Fan, Z | 1 |
| Garg, A | 1 |
| Finneran, W | 1 |
| Feld, GK | 1 |
| Koudstaal, PJ | 1 |
| Algra, A | 1 |
| Pop, GA | 1 |
| Kappelle, LJ | 1 |
| van Latum, JC | 1 |
| van Gijn, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for atenolol and Death, Sudden, Cardiac
| Article | Year |
|---|---|
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Calcium Channel Blockers; Death, Sudden, Cardiac; Dilt | 1996 |
Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Autonomic Nervous System; Cross-Over Studies; De | 1997 |
Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. Beijing Collaborative Study Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cardiac Outpu | 1997 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
11 other studies available for atenolol and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmia | 2018 |
Efficacy of different beta-blockers in the treatment of long QT syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Atenolol; Child; Child, Preschool; Death, Sudden, Ca | 2014 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Unexpected interaction between beta-adrenergic blockade and heart rate variability before and after myocardial infarction. A longitudinal study in dogs at high and low risk for sudden death.
Topics: Animals; Atenolol; Autonomic Nervous System; Death, Sudden, Cardiac; Dogs; Heart; Heart Rate; Longit | 1994 |
Beta-receptor blockade in preventing sudden death.
Topics: Adrenergic beta-Antagonists; Atenolol; Death, Sudden, Cardiac; Humans; Metoprolol; Practolol; Sotalo | 1993 |
Silent myocardial ischemia: some good news.
Topics: Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Combined Modality Therapy; Coronary | 1997 |
Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Death, Sudden, Cardiac; Electroc | 1998 |